The Worthlessness of Vitamin D Is Mildly Exaggerated: What AI Tells Us About Health Data

I’ve been building AI systems for real businesses since 2022. Not the flashy demo stuff—I’m talking about production pipelines that process thousands of data points daily. So when I saw the headline "The Worthlessness of Vitamin D Is Mildly Exaggerated," I paid attention. Not because I’m a doctor (I’m not), but because this is a perfect case study in how AI can cut through noise in health research. Here’s the thing: we’ve all heard the debates. Vitamin D is either a miracle supplement or completely useless. The truth, as usual, is somewhere in the middle. But what fascinated me was the methodology behind the analysis. Someone actually ran the numbers—properly. ## What the Data Actually Says A recent deep-dive analysis examined the relationship between vitamin D supplementation and health outcomes. The key finding? The "worthlessness" narrative is, well, mildly exaggerated. Let me break it down. The analysis looked at multiple large-scale studies, including the VITAL trial (Vitamin D and Omega-3 Trial) which tracked over 25,000 participants. The raw data shows that vitamin D supplementation doesn’t prevent cancer or cardiovascular events in the general population. That part is true. But here’s where it gets interesting: when you subset the data by baseline vitamin D levels, the picture changes. People who were actually deficient (serum levels below 20 ng/mL) did see benefits—particularly in cancer mortality reduction and autoimmune disease prevention. | Population Segment | Benefit from Supplementation | Evidence Strength | |-------------------|------------------------------|-------------------| | General population (no deficiency) | Minimal to none | Strong | | Deficient individuals (below 20 ng/mL) | Reduced cancer mortality | Moderate | | Severely deficient (below 12 ng/mL) | Multiple health benefits | Moderate-strong | | Autoimmune conditions | Reduced flare risk | Moderate | The lesson? Aggregated averages hide individual realities. This isn’t just about vitamin D—it’s about how we interpret data in the age of AI. ## Why This Matters for AI Practitioners I run an AI platform that connects to various health and analytics APIs. When I read this analysis, I immediately thought: how many businesses are making decisions based on averages? Here’s a concrete example from my own work. Last year, I built a customer churn prediction system for a SaaS company. The initial model said "email engagement doesn’t matter"—because the average engagement was low across all users. But when we segmented by user behavior, we found that power users who stopped engaging were 4x more likely to churn. The average was hiding the signal. Same thing happens in health data. When you collapse across populations, you lose the signal that matters for specific subgroups. The vitamin D analysis is a textbook case of Simpson’s paradox: a trend appears in several different groups of data but disappears when these groups are combined. ## The AI Lesson: Don’t Trust Averages The analysis I’m referencing uses Bayesian methods to re-evaluate the trial data. Instead of asking "does vitamin D work?" (a yes/no question that depends on context), it asks "for whom does it work, and under what conditions?" This is exactly what we should be doing with AI in business. Not building one-size-fits-all models, but systems that adapt to context. For example, ASI Biont supports connecting multiple data sources via API to build personalized health and business insights—because one-size-fits-all approaches fail in both domains. Let me give you three practical takeaways from this case: 1. **Check your baseline** – Before you dismiss a variable as useless, check if it matters for a subset of your data. In marketing, that might mean analyzing campaign performance by channel rather than total. 2. **Bayesian thinking wins** – The analysis uses prior probabilities and updates them with evidence. This is more honest than p-value hunting. In my AI systems, I always include Bayesian confidence intervals. 3. **Be skeptical of headlines** – "Vitamin D is worthless" is a great clickbait headline. But it’s also misleading. The same applies to "AI will replace all jobs" or "Your business is doomed without ChatGPT." Reality is nuanced. ## How to Apply This in Your Work If you’re building AI systems for decision-making, here’s a concrete protocol: - Always segment your data before drawing conclusions. Natural subgroups exist in every dataset. - Use hierarchical models that can learn from the full dataset while making predictions for subgroups. - Report uncertainty. Don’t just give point estimates—show ranges. I’ve seen companies waste hundreds of thousands on AI systems that optimized for the average user while ignoring the high-value segment. This is the same mistake as prescribing vitamin D to everyone or no one. ## Conclusion The worthlessness of vitamin D is mildly exaggerated. That’s not a medical recommendation—it’s a data literacy lesson. In health, in business, and in AI, the most dangerous phrase is "on average." If you’re building systems that process health or behavioral data, take the time to understand distributions, not just means. The difference between a useless model and a valuable one is often just a few lines of code that ask: "what about the subgroups?" [Source](https://dynomight.net/vitamin-d/) *Note: This article is based on analysis of published trial data and does not constitute medical advice. Always consult a healthcare provider before starting supplementation.*

The Worthlessness of Vitamin D Is Mildly Exaggerated: What AI Tells Us About Health Data

Comments

Recent articles

Chief AI Officer Course: How AI & Data Science Leadership Turns CTOs into AI Transformation Strategists

Product Management & Growth Course: How to Manage a Product and Scale a Business with AI Learning on asibiont.com

Claude Code Antifraud: Kolmogorov–Smirnov and the Not-So-Childish Anomalies in a Children's Olympiad

Housing Law from Scratch: How an AI Course on Asibiont.com Helps You Understand the RF Housing Code and Resolve Disputes

Your AI Butler for Yandex: Automating Taxi, Music, and Food with ASI Biont Integration

9 Demos of Gemini Omni and Gemini 3.5 in Action: Real Results from a Practitioner

Learning to Lead in a Hybrid Human-AI Enterprise: The New Playbook for 2026

Master Business Automation with AI Automation & Agents Course at Asibiont.com: Learn n8n, Make.com, and RPA Without Coding

How to Automate Your Gmail with an AI Agent: Smart Email Sorting, Drafting, and Spam Filtering That Saves Hours Weekly